Stock Track | Charles River Laboratories Plummets 5.51% on Poor Q4 Results and Weak Outlook

Stock Track02-18

Charles River Laboratories International Inc. (CRL) saw its stock plummet 5.51% intraday on Wednesday. The sharp decline followed the release of the company's fourth-quarter and full-year 2025 financial results, which showed a year-over-year decrease in both adjusted earnings and revenue.

The company reported Q4 adjusted earnings of $2.39 per diluted share, down from $2.66 a year earlier. Revenue for the quarter was $994.2 million, a decline from $1.00 billion in the prior-year period. More concerning was the GAAP operating margin of -28.5%, driven by significant non-cash intangible asset and goodwill impairments totaling hundreds of millions of dollars.

Further pressuring the stock was management's outlook. The company expects a high-teens percentage decline in adjusted EPS for the first quarter of 2026 compared to the year-ago period. Additionally, its full-year 2026 adjusted EPS guidance range of $10.70 to $11.20 came in below the FactSet consensus estimate of $11, contributing to negative investor sentiment.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1101535648?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-18 22:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1101535648","market":"us","top_or_hot":-1,"title":"Stock Track | Charles River Laboratories Plummets 5.51% on Poor Q4 Results and Weak Outlook","media":"Stock Track","content":"<p>Charles River Laboratories International Inc. (CRL) saw its stock plummet 5.51% intraday on Wednesday. The sharp decline followed the release of the company's fourth-quarter and full-year 2025 financial results, which showed a year-over-year decrease in both adjusted earnings and revenue.</p><p>The company reported Q4 adjusted earnings of $2.39 per diluted share, down from $2.66 a year earlier. Revenue for the quarter was $994.2 million, a decline from $1.00 billion in the prior-year period. More concerning was the GAAP operating margin of -28.5%, driven by significant non-cash intangible asset and goodwill impairments totaling hundreds of millions of dollars.</p><p>Further pressuring the stock was management's outlook. The company expects a high-teens percentage decline in adjusted EPS for the first quarter of 2026 compared to the year-ago period. Additionally, its full-year 2026 adjusted EPS guidance range of $10.70 to $11.20 came in below the FactSet consensus estimate of $11, contributing to negative investor sentiment.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Charles River Laboratories Plummets 5.51% on Poor Q4 Results and Weak Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Charles River Laboratories Plummets 5.51% on Poor Q4 Results and Weak Outlook\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-18 22:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Charles River Laboratories International Inc. (CRL) saw its stock plummet 5.51% intraday on Wednesday. The sharp decline followed the release of the company's fourth-quarter and full-year 2025 financial results, which showed a year-over-year decrease in both adjusted earnings and revenue.</p><p>The company reported Q4 adjusted earnings of $2.39 per diluted share, down from $2.66 a year earlier. Revenue for the quarter was $994.2 million, a decline from $1.00 billion in the prior-year period. More concerning was the GAAP operating margin of -28.5%, driven by significant non-cash intangible asset and goodwill impairments totaling hundreds of millions of dollars.</p><p>Further pressuring the stock was management's outlook. The company expects a high-teens percentage decline in adjusted EPS for the first quarter of 2026 compared to the year-ago period. Additionally, its full-year 2026 adjusted EPS guidance range of $10.70 to $11.20 came in below the FactSet consensus estimate of $11, contributing to negative investor sentiment.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CRL","symbol_name":"查尔斯河","start_time":0,"source_url":"","article_id":"1101535648","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1101535648","pubTimestamp":1771425291,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Charles River Laboratories International Inc. (CRL) saw its stock plummet 5.51% intraday on Wednesday. The sharp decline followed the release of the company's fourth-quarter and full-year 2025...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CRL":"查尔斯河"},"translate_title":"个股追踪|Charles River Laboratories暴跌5.51%Q4业绩不佳前景疲弱","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CRL":1},"content_text":"Charles River Laboratories International Inc. (CRL) saw its stock plummet 5.51% intraday on Wednesday. The sharp decline followed the release of the company's fourth-quarter and full-year 2025 financial results, which showed a year-over-year decrease in both adjusted earnings and revenue.The company reported Q4 adjusted earnings of $2.39 per diluted share, down from $2.66 a year earlier. Revenue for the quarter was $994.2 million, a decline from $1.00 billion in the prior-year period. More concerning was the GAAP operating margin of -28.5%, driven by significant non-cash intangible asset and goodwill impairments totaling hundreds of millions of dollars.Further pressuring the stock was management's outlook. The company expects a high-teens percentage decline in adjusted EPS for the first quarter of 2026 compared to the year-ago period. Additionally, its full-year 2026 adjusted EPS guidance range of $10.70 to $11.20 came in below the FactSet consensus estimate of $11, contributing to negative investor sentiment.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1101535648","isCrawlerRequest":true}